PFEPfizerSigning up patients
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung (NSCLC) · Metastatic Non Small Cell Lung Cancer · Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,410 (planned)
- Started
- Jan 6, 2026
- Main results expected
- Feb 27, 2029
- Fully finished
- Aug 26, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: Approximately 39 months
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
Measured over: Approximately 32 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07222566 · record last updated 2026-10-08 · checked 2026-11-09 15:42 UTC